Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c

Orexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $14.07 million.

According to IMS Health, 185,944 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release tablets) were filled in the fourth quarter of 2015.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge